SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

ConferenceSLS009Positive

AI Analysis

Summary

SELLAS Life Sciences presented preclinical data demonstrating SLS009 activity in pancreatic cancer models at the 2026 AACR Conference on Pancreatic Cancer. The compound is a selective CDK9 inhibitor being evaluated in patient-derived organoid models of pancreatic ductal adenocarcinoma.

Outcome Details

Preclinical data presented in patient-derived organoid models demonstrating SLS009 activity

Importance:4/10

Sentiment:

0.30

preclinicalpancreatic cancerCDK9 inhibitorAACR conferencedata presentation

Related Companies

$SLS

Read the original article

Published by GlobeNewswire Clinical Studies on September 25, 2026 5:00 PM

Read Original